Dear Shareholder

On behalf of the Board of AstraZeneca PLC (the Company), I am pleased to confirm that the Annual Report and Form 20-F Information 2017 (the Annual Report) has now been published.

What you should have received
If you have previously elected to receive the Annual Report via the AstraZeneca website, you can now access it at www.astrazeneca.com/annualreport2017.

An ‘at a glance’ summary of the Company’s performance during 2017 is included on pages 2 and 3 of this document. Useful information for shareholders is set out on page 4.

Communicating with you
I would urge shareholders who currently receive communications from the Company in hard copy to consider opting to receive all future information from the Company in electronic format. There are clear environmental benefits and cost savings arising from reduced paper usage, printing and distribution if you do so.

You can elect to receive shareholder communications in electronic format by registering your details at www.shareview.co.uk and electing for e-communications. Whenever shareholder communications are published, we will send you an email with a link to the information on the AstraZeneca website.

Annual General Meeting 2018
The Company’s Annual General Meeting will be held on 18 May 2018 at the Royal Lancaster London Hotel, Lancaster Terrace, London W2 2TY. The Notice of Annual General Meeting and Shareholders’ Circular will be sent to shareholders, in accordance with communication instructions received, in due course.

Yours faithfully

Leif Johansson
Chairman
15 March 2018

Important information
This document contains certain statements extracted from the Annual Report and Form 20-F Information 2017 (Annual Report) for AstraZeneca PLC that are neither reported financial results nor other historical information. These statements are forward-looking statements, including within the meaning of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those disclosed in our forward-looking statements.
For a description of factors that could affect future results, reference should be made to the full ‘Cautionary statement’ on page 240 of the Annual Report and to the section entitled ‘Risk’ on pages 210 to 220. This information is provided solely for the convenience of current and future members of the Company and is not intended to satisfy any statutory and/or regulatory requirements in the UK or elsewhere. Accordingly, it should only be read in conjunction with the Annual Report. The Company, its subsidiaries, Directors and officers shall not be liable for the consequence of any action taken solely in reliance on the information contained in this document.
A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.

Our Purpose is to push the boundaries of science to deliver life-changing medicines. We want to be valued and trusted by our stakeholders as a source of great medicines over the long term.

Our strategic priorities

1. Achieve Scientific Leadership
2. Return to Growth
3. Be a Great Place to Work

A science-led innovation strategy

11 new molecular entities (NMEs) in Phase III/ pivotal Phase II or under regulatory review covering 19 indications

Broad R&D platform in three main areas

Oncology: Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations. We seek to achieve this by means of exploiting the power of four scientific platforms.

Cardiovascular & Metabolic Diseases: We are following the science to transform how cardiovascular, renal and metabolic diseases are understood, interact and impact one another.

Respiratory: We aim to transform the treatment of respiratory disease with our growing portfolio of medicines and scientific research targeting disease modification.

We are also selectively active in the areas of autoimmunity, neuroscience and infection.

Portfolio of specialty and primary care products (Product Sales)

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Total Sales</th>
<th>2017</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>$4,024m</td>
<td>21%</td>
<td>$3,383m</td>
<td>2015: $2,825m</td>
</tr>
<tr>
<td><strong>Cardiovascular &amp; Metabolic Diseases</strong></td>
<td>$7,266m</td>
<td>36%</td>
<td>$8,116m</td>
<td>2015: $9,489m</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td>$4,706m</td>
<td>36%</td>
<td>$4,753m</td>
<td>2015: $4,987m</td>
</tr>
<tr>
<td><strong>Other Disease Areas</strong></td>
<td>$4,156m</td>
<td>21%</td>
<td>$5,067m</td>
<td>2015: $6,340m</td>
</tr>
</tbody>
</table>

- **Tagrisso** sales up 126% (126% at CER) and approved in more than 60 markets
- **Iressa** sales of $128 million, up 1% (3% at CER)
- **Forxiga** sales of $1,079 million, up 29% (29% at CER)
- **Nexium** sales down 4% (1% at CER) to $1,952 million
- **Synagis** sales of $687 million
- **Flumist/Fluenz** sales of $78 million, down 25% (28% at CER)
Oncology. Antibody that blocks inhibitory signals from the tumour to cells of the immune system resulting in enhanced anti-tumour immunity.

Cardiovascular & Metabolic Diseases. Messenger RNA being read by a ribosome to produce signalling proteins.

Respiratory. Eosinophil prior to apoptosis. Natural killer cell being recruited by a biologic.

Global commercial presence, with strength in Emerging Markets (Product Sales)

<table>
<thead>
<tr>
<th>Region</th>
<th>2016 Sales</th>
<th>2015 Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$6,169m</td>
<td>$5,947m</td>
</tr>
<tr>
<td>Emerging Markets</td>
<td>$6,149m</td>
<td>$5,822m</td>
</tr>
<tr>
<td>Europe</td>
<td>$4,753m</td>
<td>$5,323m</td>
</tr>
<tr>
<td>Established</td>
<td>$3,081m</td>
<td>$3,022m</td>
</tr>
<tr>
<td>Rest of World</td>
<td>$3,081m</td>
<td>$3,022m</td>
</tr>
<tr>
<td>Total</td>
<td>$23,144m</td>
<td>$21,546m</td>
</tr>
</tbody>
</table>

Commercial Highlights:
- Growth Platforms grew by 5% (6% at CER) in 2017 and represented 68% of Total Revenue
- Emerging Markets: Sales growth of 6% (8% at CER), in line with long-term ambitions. China sales in the year grew by 12% (15% at CER), supported by the launches of new medicines
- New CVMD: Sales growth of 9% (9% at CER). Strong performances from Farxiga and Brilinta, with sales exceeding $1 billion in 2017
- Respiratory: Sales declined by 1% (1% at CER). Sales of Symbicort declined by 6% (6% at CER) and Pulmicort sales rose by 11% (12% at CER)
- Japan: 1% growth in sales (4% at CER), underpinned by the growth of Tagrisso and Forxiga, partly mitigated by the impact of the entry of generic competition to Crestor in the second half of the year
- New Oncology: Sales growth of 98% (98% at CER). Sales of Tagrisso reached $955 million to become AstraZeneca’s largest-selling Oncology medicine

Our talented employees:
- Committed to achieving our Purpose in a sustainable way and upholding our Values by fostering a strong AstraZeneca culture
- 61,100 employees
  - 2016: 59,700
  - 2015: 61,500
- 100% of employees trained in new Code of Ethics

Our capital-allocation priorities:
- Striking a balance between the interests of the business, our financial creditors and shareholders, and supporting our progressive dividend policy

Distributions to shareholders
- 2016: $3,561m
- 2015: $3,486m

Dividends
- 2016: $3,519m
- 2015: $3,486m

Proceeds from issue of shares
- 2016: $(47)m
- 2015: $(43)m

Total
- 2016: $3,474m
- 2015: $3,443m

Dividend per Ordinary Share for 2017
- 1st interim dividend
  - 2016: $0.90
  - Pence: 68.9
  - SEK: 7.40
  - Payment date: 11 September 2017
- 2nd interim dividend
  - 2016: $1.90
  - Pence: 133.6
  - SEK: 14.97
  - Payment date: 19 March 2018

Total
- 2016: $2.80
- Pence: 202.5
- SEK: 22.37
- 2015: $2.80

Key:
- CER – constant exchange rate
- Figures in parentheses are used to represent negative numbers
Dividend payment and dates
The record date for the second interim dividend for 2017, payable on 19 March 2018, was 16 February 2018. The ex-dividend date was 15 February 2018. The record date for the first interim dividend for 2018, payable on 10 September 2018, is 10 August 2018. Future dividends will normally be paid as follows:

First interim: Announced in July/August and paid in September. Second interim: Announced in January/February and paid in March.

Shareholders holding Ordinary Shares directly may opt for dividends to be paid straight to their bank or building society account, rather than being paid by cheque. To elect for this swift and secure method of payment, contact the Ordinary Share registrar, visit Shareview using the link provided below, or fill in and return the mandate form sent to you with your AstraZeneca dividend cheque.

Results
Unaudited trading results of AstraZeneca in respect of the first three months of 2018 will be published on 18 May 2018 and results in respect of the first six months of 2018 will be published on 26 July 2018.

Shareview
Holders of Ordinary Shares may create a portfolio at www.shareview.co.uk to view and manage their AstraZeneca shareholding. Shareview is a free and secure online service provided by the Ordinary Share registrar that allows users to, among other things, update personal details, manage communication preferences, view dividend information and manage direct dividend payments.

ShareGift
Shareholders that hold only a small number of shares, the value of which makes it uneconomical to sell them, may wish to consider donating them to charity through ShareGift, an independent charity share donation scheme (registered charity number 1052686). Further information about ShareGift can be found on its website at www.sharegift.org or by calling +44 (0)20 7930 3737.

The Unclaimed Assets Register
AstraZeneca provides information to the Unclaimed Assets Register (UAR) relating to unclaimed dividends paid on Ordinary Shares. The UAR database provides a facility to search for financial assets that may have been forgotten and can be contacted on +44 (0)333 000 0182 or uarenquiries@uk.experian.com.

Shareholder fraud warning
Shareholders of AstraZeneca and many other companies have reported receiving unsolicited calls and correspondence relating to their shareholdings and investment matters. Shareholders are advised to be very cautious of any unsolicited approaches and to note that reputable firms authorised by the Financial Conduct Authority (FCA) are very unlikely to make such approaches. Such approaches are likely to be part of a ‘boiler room scam’ attempting to defraud shareholders.

Shareholders are advised to familiarise themselves with the information on scams available on the FCA website www.fca.org.uk/consumers and within the FAQ in the Investors section of AstraZeneca’s website, www.astrazeneca.com.

Any suspected scams or fraudulent approaches should be reported to the FCA via its website and to AstraZeneca’s Ordinary Share registrar, using the contact details on this page.